ZYC300 Uses, Dosage, Side Effects and more
ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.
| Attribute | Details |
|---|---|
| Trade Name | ZYC300 |
| Generic | ZYC300 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For the treatment of various forms of cancer.
How ZYC300 works
CYP1B1 is a unique extra-hepatic member of the cytochrome P450 family of monooxygenases. The CYP1B1 protein is over-expressed in all primary human tumors with minimal expression in critical normal tissues making this an attractive target for immunotherapy. CYP1B1-specific human T lymphocytes lyse tumor cells but not normal cells. To explore the potential clinical utility of elevated CYP1B1 immune responses, a pDNA-based immunogen was developed (ZYC300). The ZYC300 formulation is comprised of PLG microparticles containing a plasmid DNA with a CMV promoter that drives expression of mutated CYP1B1 protein.
